arrow
O

Otto Frey

Heidenheim General Hospital
H指数:23
被引数:2,788

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Vancomycin optimised dosing regimens for critically ill patients receiving renal replacement therapy

万古霉素优化给药方案用于接受肾脏替代治疗的危重患者

2026-08-040
OA
Pharmacokinetics, target attainment and outcomes of piperacillin/tazobactam in critically ill patients receiving continuous infusion with therapeutic drug monitoring: a retrospective analysis

哌拉西林/他唑巴坦在危重患者中连续输注并接受治疗药物监测的药代动力学、靶点达峰及疗效:一项回顾性分析

2026-04-170
OAAI
Meropenem and piperacillin/tazobactam optimised dosing regimens for critically ill patients receiving renal replacement therapy

美罗培南和哌拉西林/他唑巴坦针对接受肾脏替代治疗的危重患者的优化给药方案

2025-08-130
OA
Meropenem plasma concentrations in critically ill patients treated with the novel multi organ replacement therapy ADVOS

美罗培南在采用新型多器官替代疗法ADVOS治疗的危重患者血浆中的浓度

2025-05-210
OA
Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus

达巴万星长期抑制性疗法在金黄色葡萄球菌引起的左心室辅助装置感染中的探索性分析

2025-05-030
OA
Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting
2023-07-1313
OAAI
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial (vol 48, pg 311, 2022)
2022-03-182
OAAI
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial

基于治疗药物监测的哌拉西林/他唑巴坦剂量优化对脓毒症相关器官功能障碍影响的随机对照试验

2022-02-01107
OAAI